News | 02 September 2023
Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Meningitis still affects more than 2.5 million people globally each year
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Propranolol LA is a generic equivalent of Inderal LA
Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
The company is committed to address the observations and will submit its response to US FDA within the stipulated time
Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
The company has entered into a three-year Deferred Prosecution Agreement
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Eris Lifesciences enters into term loan agreement with Citi Bank
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Subscribe To Our Newsletter & Stay Updated
